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Abstract
Background: It is plausible that optimal cardiovascular disease (CVD) risk management differs in patients with
rheumatoid arthritis (RA) from low or middle income compared to high income populations. This study aimed at
producing evidence-based points to consider for CVD prevention in South African RA patients.
Methods: Five rheumatologists, one cardiologist and one epidemiologist with experience in CVD risk management
in RA patients, as well as two patient representatives, two health professionals and one radiologist, one
rheumatology fellow and 11 rheumatologists that treat RA patients regularly contributed. Systematic literature
searches were performed and the level of evidence was determined according to standard guidelines.
Results: Eighteen points to consider were formulated. These were grouped into 6 categories that comprised overall
CVD risk assessment and management (n = 4), and specific interventions aimed at reducing CVD risk including RA
control with disease modifying anti-rheumatic drugs, glucocorticoids and non-steroidal anti-inflammatory drugs
(n = 3), lipid lowering agents (n = 8), antihypertensive drugs (n = 1), low dose aspirin (n = 1) and lifestyle
modification (n = 1). Each point to consider differs partially or completely from recommendations previously
reported for CVD risk management in RA patients from high income populations. Currently recommended CVD risk
calculators do not reliably identify South African black RA patients with very high-risk atherosclerosis as represented
by carotid artery plaque presence on ultrasound.
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Conclusions: Our findings indicate that optimal cardiovascular risk management likely differs substantially in RA
patients from low or middle income compared to high income populations. There is an urgent need for future
multicentre longitudinal studies on CVD risk in black African patients with RA.
Keywords: Cardiovascular disease risk management, Rheumatoid arthritis, Low to middle income countries, South Africa
Background
Patients with rheumatoid arthritis (RA) reportedly experi-
ence a markedly increased risk of atherosclerotic cardiovas-
cular disease (CVD) [1, 2]. Meta-analyses documented a ~
50% increase in cardiovascular event and mortality rates in
RA [3, 4]. Atherogenesis in RA remains poorly understood
but clearly differs from that in non-RA persons [1, 2, 5–9].
In this regard, besides traditional cardiovascular risk factors
(CVRF), disease characteristics and a genetic component
are implicated in the increased atherogenesis among pa-
tients with RA [5–13]. Accordingly, CVD risk calculators
based on traditional CVRF including the Framingham score
and Systematic Coronary Risk Evaluation (SCORE), were
found to underestimate the actual cardiovascular risk in RA
[14–16]. In 2010, a European League Against Rheumatism
(EULAR) task force reported recommendations for CVD
risk management in RA patients [1]. A Spanish group of in-
vestigators [2] and EULAR [17] subsequently updated these
recommendations in 2014 and 2016, respectively. The evi-
dence on which these recommendations is based originates
in high income populations [1, 2].
During the past ~ 40 years, the CVD incidence has
decreased in high income countries [18]. By contrast,
during the same period, the CVD burden has markedly
increased in low and middle income countries [18]. Con-
sequently, more than 80% of the global CVD mortality
burden now occurs in low and middle income popula-
tions [19]. The increase in incident CVD in low and
middle income countries is attributable to rapid
urbanization and its consequent changes in epidemio-
logic health transition stages [19, 20]. CVRF profiles and
their impact on CVD as well as cardiovascular event
phenotypes differ among low or middle compared to
high income populations [19–21]. In this regard, Sub-
Saharan Africa comprises a region with a population of
over one billion persons [22] and mostly low, to a lesser
extent middle and no high income countries [23–25].
Sub-Saharan Africa is characterized not only by poverty
but also by large inequalities [26]. The latter are due, at
least in part, to previous colonialism and systems like
apartheid [19]. Eight of the top 10 most unequal coun-
tries in the world are located in Sub-Saharan Africa [26].
Notably in the present context, although South Africa is
overall a middle income country according to the World
Bank [23], it is the most unequal country in the world
with a Gini coefficient of 0.68 [27]. Indeed, to date, black
South Africans still earn 5 times less than their white
counterparts [27] and, overall, only one in four South
Africans can currently be considered as either stable
middle class or above in terms of means [28]. Age-
standardized death rates due to CVD are currently much
larger in black compared to white South Africans [29].
The estimated South African population was 57.7 mil-
lion in 2018 [30]. The prevalence of RA in Sub-Saharan
Africa is not dissimilar from that in high income popula-
tions [31].
Taken together, it is plausible that optimal CVD risk
assessment and management differs in patients with RA
from low or middle income compared to high income
populations. Herein, we reviewed reported evidence on
cardiovascular disease risk in South African black and
white African RA patients. We subsequently aimed at for-
mulating concise, yet comprehensive points for consider-
ation in CVD risk management among Sub-Saharan
African patients with RA, taking into consideration recent
recommendations that originated in high income coun-
tries [2, 17]. The target users of this study are RA patients
and health care providers that manage their disease.
Methods
This study was performed in line with the Appraisal of
Guidelines for Research instrument (AGREE II) [32].
The work group comprised (1) five rheumatologists (AS,
PHD, MAG-G, SC, AES), one cardiologist (CG-J) and
one epidemiologist (JL) with experience in CVD risk
management in patients with RA (expert panel (EP)), (2)
two patient representatives, two health professionals and
one radiologist, and (3) eleven rheumatologists that
regularly treat RA patients, were selected by the EP and
contributed by revising the manuscript critically, provid-
ing their level of agreement for each recommendation
and reading and approving the final version. The local
rheumatologists (AS, PHD and AES) that formed part of
the EP held several meetings throughout. Input from
other EP contributors was obtained regularly through
online communications.
The study was performed in 4 stages. In stage 1, AS and
PHD reviewed existing American, European and Sub-
Saharan African recommendations on CVD risk assessment
and management in the general population and in patients
with RA, and on the treatment of RA [1, 2, 17, 33–42]. In
stage 2, based on the obtained information, core questions
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for the systematic literature review (SLR) were formulated
by the EP members as guided by the Preferred Items for
Systematic Reviews and Meta-analyses (PRISMA) state-
ment [43]. In stage 3, the SLR was performed by AS and
PHD up to 12/2018. The Wiley/Cochrane Library and
Pubmed/Medline were searched. For our main SLR, the
following search terms were used: ‘rheumatoid arthritis’,
‘Africa’ and ‘cardiovascular disease risk’ or ‘cardiovascular
disease’ or ‘myocardial infarction’ or ‘stroke’ or ‘heart fail-
ure’ or ‘atherosclerosis’ or ‘endothelial dysfunction’ or
‘arterial function’ or ‘left ventricular function’, or ‘treat-
ment’. We additionally performed a Pubmed search on
meta-analyses and systematic reviews on CVD risk in the
general Sub-Saharan African population using the search
terms ‘Africa’, ‘cardiovascular disease’ and ‘systematic re-
views’ or ‘meta-analyses’. Finally, as the SLR for the recent
EULAR recommendations on cardiovascular risk manage-
ment in high income populations ended in 02/2015, we
searched for systematic reviews and meta-analyses on CVD
risk in RA using the search terms ‘rheumatoid arthritis’,
‘cardiovascular disease’ and ‘systematic reviews’ or ‘meta-
analyses’ that were published between 02/2015 and 12/
2018, on Pubmed. We also identified additional relevant
papers by a manual search of the reference lists of the re-
trieved manuscripts. Furthermore, we included 3 publica-
tions (references [22, 44, 45]) that were reported after 12/
2018 in view of their perceived relevance in the present
context. After removal of duplicates, titles and abstracts
were screened for suitability. Full text articles were assessed
for eligibility.
In stage 4, the EP formulated the points to consider.
The level of evidence was determined according to the
Oxford Centre of Evidence-based Medicine Levels of
Evidence [46], and the strength of point to consider in
agreement with 2014 Update of the EULAR standardised
operating procedures for EULAR-endorsed recommen-
dations [47]. When the underlying evidence was ob-
tained in the general population and there was no
reason to suggest that the derived points to consider
would differ in Sub-Saharan African patients with RA,
the level of evidence was left unaltered but the strength
of point to consider was reduced by one level. The for-
mulated points to consider were then discussed by AS,
AES and PHD with the involved patient representatives,
health professionals and rheumatology fellow during a
separate meeting. This was done in order to facilitate
their contribution to the study. Finally, the drafted
manuscript was sent by email to each contributor for
further intellectual input and level of agreement rating
with each point to consider on a scale of 0 to 10. The
obtained ratings were averaged and are presented as
mean (SD). The level of evidence in support of each
point to consider ranged from 1A to 3. Therefore, we
did not consider it to be necessary to apply the Delphi
method for reaching agreement in the current points to
consider.
Results
The core questions for our main search are presented in
supplementary Table 1. The flow chart and selection
process for our main SLR are given in Fig. 1. Overall, we
included only manuscripts on human research and 266
articles were identified initially. Upon perusal of the
Titles and Abstracts, 82 papers were excluded as they
comprised of duplicates or were considered not eligible.
The remaining 184 manuscripts were searched and read
through. A further 101 articles were excluded as their
content did not address our research questions or was
Fig. 1 Flow chart and selection process for the main literature search. RA: rheumatoid arthritis
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considered redundant, thereby leaving us with 83 studies
for inclusion in the study. All Sub-Saharan African stud-
ies that included RA patients originated in South Africa.
The EP formulated 18 points to consider grouped into 6
categories that included (1) overall CVD risk assessment
and management (n = 4) and specific interventions aimed
at reducing CVD risk comprising (2) RA control with dis-
ease modifying agents anti-rheumatic drugs (DMARD),
glucocorticoids and non-steroidalanti-inflammatory drugs
(NSAID) (n = 3), (3) lipid lowering agents (n = 8), (4) anti-
hypertensive agents (n = 1), (5) low dose aspirin (n = 1)
and (6) lifestyle modification (n = 1). These are presented
in Table 1.
Overall CVD risk assessment
The EULAR recommendations for cardiovascular risk
management in patients with RA and other inflammatory
joint diseases state that clinicians should be aware of the
increased CVD risk in RA compared with the general
population [17]. Since RA characteristics contribute to
CVD beyond traditional CVRF in high income populations
[5–8], disease specific recommendations on cardiovascular
risk management are indeed justified and necessary. How-
ever, in 3 recently reported case control studies that were
performed in high income countries, RA was not signifi-
cantly associated with increased cardiovascular mortality
among patients with a disease onset subsequent to year
2000 [48, 49] or 2003 [50]. This change over time is likely
due to improved RA control. Importantly in the present
context, a recent case control study in black Africans docu-
mented that the overall traditional cardiovascular risk bur-
den, C-reactive protein concentrations and atherosclerosis
burden as estimated by carotid intima-media thickness,
were each similar in treated established RA compared to
non-RA participants [51]. Also, C-reactive protein and
interleukin-6 concentrations were not related to disease
activity and severity measures in black African RA patients
[51]. RA may therefore currently not impact atheroscler-
otic CVD in this population [51].
Sub-Saharan African black persons are reported to
experience large mortality rates from cerebrovascular
disease and hypertensive heart disease but a markedly
low frequency of ischemic heart disease [29]. Due to
their low income status, they are mostly not members of
private sector medical schemes [52]. Therefore, black
Africans seek medical care mostly in the public health-
care sector where resources are markedly restricted [52].
The overall traditional and non-traditional CVD risk
burdens are larger in black compared to white Africans
with RA [53, 54], and also larger in African RA patients
that attend public compared to private healthcare facil-
ities [55]. Further, atherosclerosis extent as represented
by carotid artery intima-media thickness and the preva-
lence of plaque is currently as extensive in black
compared to white Africans with RA [56]. We therefore
suggest to perform overall CVD risk assessment in all
African RA patients irrespective of population origin and
socioeconomic status (point to consider (PTC) 1.1).
Similar to EULAR [17], we suggest to perform 5 yearly
CVD risk evaluation in RA patients that experience low
CVD risk (PTC1.2). In addition, based on findings re-
ported in the general population [33, 34], we suggest to
perfrom at least yearly CVD risk assessment in patients
that are at high or very high risk (PTC1.2).
EULAR states that the rheumatologist should ensure
that CVD risk management is performed in patients
with RA, either by her- or himself or other healthcare
providers [17]. Who should assess and manage CVD risk
in African patients with RA? In the case control study
among black Africans that was alluded to above [51],
blood pressure values were similar and lipid concentra-
tions were more favourable in RA patients compared to
controls. Yet, antihypertensive agents and statins were
prescribed in 53.9 and 40.2% (p = 0.02 for difference),
and 19.3 and 0% of RA and control participants that
sought medical care in non-rheumatology public health-
care settings, respectively [51]. We therefore suggest
that, at this point in time, the rheumatologist should
perform primarily CVD risk evaluation and management
in African patients with RA (PTC1.3).
Compared to EULAR [17], we additionally suggest that
(1) cardiovascular risk profiles and (2) potential benefits,
(3) side effects and (4) drug-drug interactions as well as
(5) patient preferences are discussed between the clinician
and RA patient to facilitate informed decision making and
intervention adherence and continuation (PTC1.4). This is
in line with the 2018 Guideline on the Management of
Blood Cholesterol [35]. Non-adherence to cardiovascular
drug use is frequent (~ 50%) [57] and associated with in-
creased CVD risk in the general population [58]. In this
regard, Lindhardsen and colleagues reported that initi-
ation and adherence to secondary prevention pharmaco-
therapy was even lower in RA compared to non-RA
patients [57]. De Vera and colleagues further documented
that statin discontinuation increased the risk of acute
myocardial infarction in RA, as applies to the general
population [59]. It is further pertinent in the present con-
text that low income status and education level as well as
depressive symptoms [60, 61], all of which are each highly
prevalent in Sub-Saharan black persons [27], contribute to
intervention non-adherence or/and discontinuation [62].
Specific interventions aimed at reducing CVD risk
RA control
In agreement with EULAR [17], we suggest targeting op-
timal RA control in order to reduce CVD risk in RA
(PTC2.1.1). Ample evidence was reported that cumula-
tive inflammation is associated with CVD risk and that
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Table 1 Points to consider in cardiovascular disease risk management among South African black and white patients with RA
LoE SoR LoA (SD)
1. Overall CVD risk assessment and management
1.1 We suggest to perform overall CVD risk assessment in all RA patients irrespective of population
origin and socioeconomic status.
3 C 9.8 (0.5)
1.2 We suggest to perform overall CVD risk assessment upon initial presentation and subsequently
at least every 5 years in RA patients at low risk, and at least yearly in those at high or very high risk.
3 C 9.7 (0.6)
1.3 We suggest that the treating rheumatologist performs primarily CVD risk assessment and
management in patients with RA.
3 C 9.4 (0.9)
1.4 We suggest that (1) cardiovascular risk profiles and (2) potential benefits, (3) side effects and (4)
drug-drug interactions as well as (5) patient preferences are consistently discussed between the
clinician and RA patient in order to facilitate informed decision making and intervention adherence
and non-discontinuation.
3 C 9.9 (0.4)
2. Specific interventions aimed at reducing CVD risk
2.1 RA control
2.1.1 We suggest targeting optimal RA control and, in the absence of contraindications, to consider
including (hydroxy) chloroquine in DMARD regimens to reduce CVD risk in RA patients.
1B-3 A-C 9.4 (0.8)
2.1.2 We suggest considering the use of intra-articular glucocorticoids as bridge therapy upon
initiating or intensifying conventional synthetic DMARD in order to reduce CVD risk in RA.
3 C 9.0 (1.4)
2.1.3 We suggest using NSAID sparingly in patients with RA, particularly amongst those at high or
very high CVD risk including the presence of chronic kidney disease, and with hypertension. We
recommend the preferential use of naproxen (with a proton pump inhibitor). NSAID use is not
recommended in RA patients with heart failure.
1A-3 B-C 9.6 (0.7)
2.2 Lipid lowering agents
2.2.1 In RA patients with very high CVD risk comprising (1) established CVD, (2) diabetes mellitus
with target organ damage or major CVD risk factors, and (3) severe chronic kidney disease, we
suggest using high dose statin therapy targeting an LDL-C level of 1.8 mmol/l. In RA patients with
high CVD risk comprising (1) diabetes without target organ damage or other major CVD risk factors,
(2) moderate chronic kidney disease, and (3) severe dyslipidemia (total cholesterol >/= 8.0 mmol/
l or/and LDL-C level >/= 4.9 mmol/l), we suggest using moderate to high dose statin therapy
targeting an LDL cholesterol level of 2.5 mmol/l.
1A-3 B-C 9.7 (0.6)
2.2.2 In RA patients without (1) established CVD, (2) diabetes, (3) moderate or severe chronic kidney
disease, or (4) severe dyslipidemia, we suggest refining CVD risk assessment by carotid and femoral
artery ultrasound when accessible to identify plaque presence, which represents very high CVD risk
and an indication for high dose statin therapy. This is particularly important in black African
RA patients.
3 C 9.5 (0.7)
2.2.3 In black RA patients without access to carotid and femoral ultrasound, we suggest to consider
the presence of a CKD-EPI estimated estimated glomerular filtration rate of < 80ml/min/1.73m2 as
an indication for high-dose statin therapy.
3 C 9.3 (1.1)
2.2.4 In white RA patients without access to carotid and femoral ultrasound, we suggest to consider
the presence of a Framingham score score of > 7.5% as an indication for high-dose statin therapy.
3 C 9.7 (0.5)
2.2.5 In black RA patients without (1) CVD, (2) diabetes, (3) moderate or severe chronic kidney
disease, (4) severe dyslipidemia and (5) carotid or/and femoral plaque existence, we suggest to
consider the presence of a CKD-EPI determined glomerular filtration rate of < 80ml/min/1.73m2 as
an indication for moderate dose statin therapy.
1A B 9.2 (1.1)
2.2.6 In white RA patients without (1) CVD, (2) diabetes, (3) moderate or severe chronic kidney
disease, (4) severe dyslipidemia and (5) carotid or/and femoral plaque, we suggest to consider the
presence of a Framingham score of > 7.5% as an indication for moderate dose statin therapy.
1A B 9.3 (0.8)
2.2.7 When affordable, we suggest the additional use of ezetimibe in RA patients when the LDL-C
target is not met despite maximally tolerated statin doses. In RA patients who are intolerant to
statin therapy, we suggest the alternative use of ezetimibe. When affordable, we suggest referral to
a lipidologist for consideration of additional treatment with a proprotein convertase subtilisin/kexin
9 inhibitor in RA patients with established ACVD and severe dyslipidemia that have persistently
high LDL-C levels despite maximally tolerated statin therapy and ezetimibe.
1B-3 B-D 9.7 (0.5)
2.2.8 We suggest lipid profile re-evaluation in RA patients subsequent to (1) obtaining low RA
activity or remission due to changes in DMARD therapy, (2) major changes in life style factors and
(3) one to three months after initiation or intensification of lipid lowering therapy to determine
whether the LDL-C target is met. We suggest lifelong use of lipid lowering agents in RA patients
with very high or high CVD risk.
1A-3 B-C 9.7 (0.6)
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controlling disease activity reduces this risk in RA pa-
tients from high income populations. In Africans with
RA, circulating interleukin-6 concentrations independ-
ently contribute 18% to overall endothelial activation
[63]. This interleukin 6-overall endothelial activation
relationship is as strong in black compared to white
Africans with RA [63]. In a longitudinal study among
Africans with RA, disease activity control with intra-ar-
ticular methylprednisolone acetate followed by conven-
tional synthetic DMARD therapy resulted in markedly
decreased interleukin-6 levels that were strongly associated
with reduced endothelial activation [64].
Since the most recent EULAR recommendations for
cardiovascular disease risk management in patients
with RA and other inflammatory disorders [17] were
published, Rempenault and colleagues reported a sys-
tematic review and meta-analysis on the metabolic
and cardiovascular benefits of hydroxychloroquine in
patients with RA [65]. The use of hydroxychloroquine
improved lipid profiles and reduced incident diabetes
and CVD as well as insulin resistance in RA [66]. In
South Africa, chloroquine can be prescribed whereas
the use of hydroxychloroquine requires an additional
request from the Medicine Control Council. Chloro-
quine is independently associated with improved lipid
profiles among Africans with RA [65]. Given these re-
cently reported findings, we additionally suggest to
consider including (hydroxy) chloroquine in DMARD
regimens to reduce CVD risk in RA patients, this in
the absence of contraindications (PTC2.1.1).
Conventional synthetic DMARD take time to sup-
press RA activity [40]. Consequently, oral glucocorti-
coids are mostly recommended and used as bridge
therapy upon conventional synthetic DMARD initi-
ation or intensification [40–42]. However, in a recent
meta-analysis of 34 observational studies or random-
ized controlled trials, glucocorticoids increased the
relative risk of cardiovascular events by 47% (95% CI
34 to 60%) in RA [67]. As an alternative to oral glu-
cocorticoids, the use of intra-articular glucocorticoids
was shown to be highly effective when used as bridge
therapy in several RA studies [64, 68, 69]. The use of
intra-articular glucocorticoids takes advantage of its
rapid non-genomic therapeutic effects [70]. In studies
performed among Africans with RA, compared to oral
glucocorticoids, intra-articular glucocorticoids were
more favourably associated with glucose metabolism
[71, 72]. As previously described, intra-articular gluco-
corticoid therapy in combination with conventional
synthetic DMARD reduced endothelial activation in
Africans with RA [64]. The use of intra-articular ra-
ther than oral glucocorticoids in RA further translates
in markedly smaller cumulative doses over time [72].
In view of these reported evidences, we suggest con-
sidering the use of intra-articular glucocorticoids as
bridge therapy upon initiating or intensifying
Table 1 Points to consider in cardiovascular disease risk management among South African black and white patients with RA
(Continued)
LoE SoR LoA (SD)
2.3 Antihypertensive agents
2.3.1 We suggest considering the use of antihypertensive agents in RA patients with a SBP
of 130–139mmHg or/and DBP of 80–89mmHg and elevated overall CVD risk, and in all
patients with SBP > 140mmHg or/and DBP > 90mmHg. Preferred first line agents
comprise angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium
channel blockers and diuretics. Preferred second line agents include spironolactone,
hydralazine and minoxidil. We suggest that calcium channel blockers should be included
in initial antihypertensive combination regimens in black Sub-Saharan African RA patients.
We suggest yearly, monthly and three monthly blood pressure measurement in normotensive
RA patients, and those with uncontrolled and controlled hypertension, respectively.
1B-3 B-C 9.6 (0.6)
2.4 Low dose aspirin use
2.4.1 We suggest using low dose aspirin as secondary prevention in RA patients with established
atherosclerotic CVD. We suggest not to use aspirin as primary intervention in RA patients
without CVD.
1A-3 B-C 9.6 (0.6)
2.5 Lifestyle factors
2.5.1 We suggest to address the importance of healthy eating habits, adequate physical activity,
stress and depressive symptom control and smoking and smokeless tobacco cessation with
consideration of Sub-Saharan Africa specific aggravating factors and in order to reduce CVD risk at
presentation and thereafter at least yearly in patients with RA.
1A-3 B-C 9.8 (0.4)
LoE level of evidence, SoR strength of recommendation, LoA level of agreement; RA: rheumatoid arthritis, CVD: cardiovascular disease; DMARD disease modifying
anti-rheumatic drugs., NSAID non-steroidal anti-inflammatory drugs LDL-C low-density lipoprotein cholesterol CKD-EPI Chronic Kidney Disease
Epidemiology Collaboration
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conventional synthetic DMARD in order to reduce
CVD risk in RA (PTC2.1.2).
In accordance with EULAR [17] and recommenda-
tions for management of cardiovascular risk in patients
with RA as reported by Martin-Martinez and col-
leagues in 2014 [2], we suggest NSAID to be used
sparingly in patients with RA, particularly in those at
high or very high CVD risk including the presence of
chronic kidney disease, and with hypertension
(PTC2.1.3). Our literature search identified a meta-
analysis of 754 trials that reported effects of NSAID
on vascular and gastrointestinal events [73]. Naproxen
was the only NSAID that did not increase major car-
diovascular events, major coronary events, stroke and
mortality [73]. All NSAID approximately doubled heart
failure risk [73]. Naproxen was however most fre-
quently associated with upper gastrointestinal compli-
cations [73]. We therefore additionally suggest to
preferentially use naproxen with a proton pump in-
hibitor, and not to use NSAID therapy in RA patients
with heart failure (PTC2.1.3).
Lipid lowering agents
In keeping with recommendations for CVD risk man-
agement in the general population [33–36], we suggest
the use of high dose statin therapy targeting a low
density lipoprotein LDL-cholesterol target of 1.8
mmol/l for RA patients in very high risk categories
(PTC2.2.1). For RA patients in high CVD risk categor-
ies, the recommended LDL cholesterol target is 2.5
mmol/l. This can mostly be achieved by using moder-
ate dose statin therapy except for in patients with se-
vere dyslipidemia. We therefore suggest the use of
moderate to high dose statin therapy for patients in
high CVD risk categories (PTC2.2.1). We specifically
state the different very high and high CVD risk cat-
egories in the current points to consider to encourage
and facilitate their use in clinical practice.
EULAR [17] recommends the application of cardio-
vascular risk calculators that were produced for use
in the general population, such as the Systematic Cor-
onary Risk Evaluation (SCORE) and Framingham
score. These calculators are based on major trad-
itional CVRF profiles. Application of a 1.5 multiplica-
tion factor for the presence of RA is additionally
recommended [17]. Also, screening for asymptomatic
atherosclerotic plaques by use of carotid ultrasound
may be considered as part of CVD risk evaluation in
patients with RA [17]. In contrast to EULAR [17], we
suggest to refine CVD risk assessment by carotid and
femoral ultrasound when accessible, in all RA patients
that do not have very high or high CVD risk profiles
(PTC2.2.2). This is particularly important in black
African RA patients [56, 74] (see below). We
recommend including femoral in addition to carotid
ultrasound as 25% of RA patients were reported to
have isolated femoral artery plaque [75]. As applies to
the general population [33, 34], we also suggest the
use of high dose statin therapy in RA patients with
carotid plaque (PTC2.2.2).
The reasons for suggesting refinement of CVD risk
evaluation in the present context are as follows. Firstly,
traditional CVRF including blood pressure, lipid parame-
ters, excess adiposity and metabolic syndrome criteria
are associated with atherosclerosis in white but not black
Africans with RA [54, 56, 74]. Similarly, the Framingham
score is associated with atherosclerosis in white but not
black Africans with RA [56, 74]. Indeed, in an inter-
national 3 centre study that included RA patients with-
out established CVD, diabetes and moderate of severe
chronic kidney disease, receiver operator characteristic
curve analysis revealed that the Framingham score and
SCORE performed similarly in identifying white Spanish
and white SSA RA patients with very high risk athero-
sclerosis as evidenced by carotid plaque presence,
whereas the respective cardiovascular risk calculators
did not discriminate black African patients with and
without plaque [76]. These reported data indicate that
cardiovascular risk calculators are not reliable in identi-
fying black African RA patients with severe subclinical
atherosclerotic CVD.
Secondly, cardiovascular risk calculators including the
Framingham score and SCORE also often underestimate
atherosclerotic CVD risk in white patients with RA [13,
14, 77, 78]. Indeed, in predominantly white Africans with
RA, the mean Framingham score in those with carotid
plaque is only 7% [77], which reportedly represents low
CVD risk and is therefore not an indication for statin
therapy. In white Spanish RA patients, 63% of those with
a EULAR modified SCORE of 1 to 4% (presumed inter-
mediate or moderate CVD risk) have carotid plaque
[14]. In white Spanish women with RA and a SCORE of
zero (low risk), 24% had carotid plaque [78]. These data
indicate that cardiovascular risk calculators also perform
sub-optimally in identifying severe atherosclerotic CVD
among white RA patients. In keeping with these find-
ings, investigations that were performed among patients
from high income populations revealed that cardiovascu-
lar risk calculators perform sub-optimally in predicting
incident CVD events in RA [13, 15].
Carotid and femoral artery ultrasound is an inexpen-
sive and non-invasive investigation that is accessible in
both the public and private healthcare sector in South
Africa. This may however not consistently apply in other
Sub-Saharan African countries. Which alternative mea-
sures are useful in estimating atherosclerotic CVD in the
present context? Previous general population studies
documented that black Americans are at higher risk of
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developing chronic kidney disease than their white coun-
terparts [79]. Chronic kidney disease was associated with
myocardial infarction and fatal coronary heart disease in
black but not white Americans [80]. Even mildly reduced
estimated glomerular filtration rate increases the risk of
incident atherosclerotic CVD [81]. RA enhances the in-
cidence of chronic kidney disease [82]. In a cohort study
that consisted of African RA patients, the Chronic Kid-
ney Disease Epidemiology Collaboration estimated glom-
erular filtration rate (CKD-EPI eGFR) was reduced to <
90ml/min/1.73m2 among 49.1 and 30.6% of black and
white participants, respectively [82]. In receiver operator
characteristic curve analysis, the CKD-EPI eGFR pre-
dicted the presence of carotid artery plaque to a clinic-
ally useful extent among black RA patients [83]. The
optimal cut-off value for the CKD-EPI was 82ml/min/
1.73m2 with a corresponding sensitivity of 42% and spe-
cificity of 91%. A CKD-EPI eGFR of < 82ml/min/1.73m2
was associated with a 2.22 fold increased prevalence of
carotid plaque in black African RA patients [83]. We
therefore suggest that in black African patients without
access to carotid ultrasound, the presence of a CKD-EPI
eGFR of < 80 ml/min/1.73m2 is considered an indication
for high dose statin therapy (PTC2.2.3).
In the 3 centre cohort study among Spanish and sub-
Saharan African RA patients that was previously referred
to, at a cut-off value of as low as 7.3%, the Framingham
score discriminated Spanish and African white RA pa-
tients with and without carotid plaque with sensitivities
and specificities of 80 and 63%, and 67 and 72%, respect-
ively [76]. Notably, at a Framingham score cut-off value
of 20% that represents high risk in the general popula-
tion of high income countries, the respective sensitivities
were inadequately low at 25 and 21% in Spanish and
white African patients with RA, respectively [76]. We
therefore suggest that in African white RA patients that
do not have access to carotid ultrasound, the presence of
a Framingham score of > 7.5% is considered an indica-
tion for high dose statin therapy (PTC2.2.4).
Cardiovascular risk factors can cause endothelial dys-
function with consequent cardiovascular events even in
the absence of marked atherosclerosis [84]. Notably in
the present context, based on several meta-analyses, the
recent American guidelines on the management of blood
cholesterol recommend the use of moderate dose statin
therapy in persons and even more so in RA patients at
intermediate risk of CVD as represented by a calculated
10 year CVD risk of > 7.5 to 20% [35]. Also, a recent
meta-analysis on the effects of statins on cardiovascular
events in patients with mild to moderate chronic kidney
disease documented that statin therapy reduced cardio-
vascular outcomes and total mortality as strongly in par-
ticipants with mild compared to moderate chronic
kidney disease [85]. In view of these evidences and given
reported findings among African persons with RA [74, 83],
when plaque absence is confirmed by carotid and femoral
ultrasound, we suggest using moderate dose statin therapy
in African black RA patients with a CKD-EPI eGFR of < 80
ml/min/1.73m2 (PTC2.2.5) and white patients with a
Framingham score of > 7.5% (PTC2.2.6). Points to consider
2.2.1 to 2.2.6 are further illustrated in Fig. 2. Exam-
ples of moderate and high dose statin therapy are also
given in Fig. 2.
Despite their proven efficacy and remarkable safety,
statins are not always sufficient to reach recommended
LDL-cholesterol targets in individual patients. Based on
findings in the general population [35, 36], when afford-
able, we suggest using ezetimibe in RA patients when
the LDL-C target is not reached despite maximally toler-
ated statin doses (PTC2.2.7). After consideration of costs
involved, drug cost value and related affordability, we
also suggest referral to a lipidologist for potential add-
itional treatment with a proprotein convertase subtilisin/
kexin 9 inhibitor in RA patients with established athero-
sclerotic CVD and severe dyslipidemia that have persist-
ently high LDL-cholesterol levels despite maximally
tolerated statin therapy and ezetimibe (R2.2.7) [35, 36].
This should be viewed in light of recently reported stud-
ies including the ODYSSEY Outcomes trial [86].
As applies to EULAR [17], we suggest lipid profile re-
evaluation after obtaining low RA activity or remission
due to changes in DMARD therapy (PTC2.2.8). Excess
adiposity is associated with adverse lipid profiles and in-
creased blood pressure and glucose concentrations to a
similar extent in black and white African women with
RA [74]. A longitudinal study among African patients
with RA documented clinically relevant effects of both
DMARD and dietary intervention on lipid concentra-
tions [87]. In view of these findings together with those
reported in the general population [34, 35], we addition-
ally suggest to reassess lipid profiles subsequent to major
changes in life style factors and one to 3 months after
initiation or intensification of lipid lowering therapy to
determine whether the LDL-cholesterol target is met
(PTC2.2.8). As previously stated, lipid lowering agent
discontinuation increases CVD risk in the general popu-
lation [58] as well as RA patients [59]. We therefore sug-
gest lifelong use of lipid lowering agents in RA patients
with very high or high CVD risk (PTC2.2.8).
Antihypertensive agents
Point to consider 2.3.1 deals with the treatment of
hypertension in African patients with RA. Hypertension
is the main CVD risk factor in Sub-Saharan Africa [88].
A systematic analysis of data from 199 countries re-
vealed that the age-standardized mean systolic blood
pressure in 2008 was larger in Sub-Saharan Africa than
in Western Europe and North-America [89]. A recent
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meta-analysis reported a pooled hypertension prevalence
of 30% in Sub-Saharan Africa [90]. Among Sub-Saharan
African persons with hypertension, overall, only 27% are
aware of their hypertension status, only 18% are treated
and only 7% have controlled hypertension [90]. It is
therefore not unexpected that the age-standardized inci-
dence of stroke is currently larger in Sub-Saharan Africa
than in high income countries [91, 92]. Further, hyper-
tension, rather than ischemic heart disease as applies to
high income countries, is the most common cause of
heart failure in Sub-Saharan Africa [93].
Hypertension is more prevalent in black compared to
white and other Africans with RA [94]. Black African
RA patients also experience less adequate blood pressure
control than their white counterparts [83]. Blood pres-
sure related cardiovascular and renal complications are
more common and severe in black compared to age
matched white patients at any blood pressure level [38].
During the recent past, controversy has arisen about
hypertension definitions and target blood pressure in the
general population [95]. The use of antihypertensive
agents is mostly recommended for primary intervention
in patients with stage 1 hypertension (systolic blood
pressure (SBP) = 140 to 159 mmHg or diastolic blood
pressure (DBP) = 90 to 99mmHg) in association with
elevated overall atherosclerotic CVD risk, and in all
patients with a SBP > 160 or DBP > 100mmHg. Indeed,
this approach is currently recommended in South Africa
[39] and is still endorsed by the 2018 European guide-
lines for the management of arterial hypertension [38].
By contrast, based on recently reported evidence, the
2017 American Hypertension Guideline [37] now cate-
gorizes persons with a SBP of 130 to 139mmHg or DBP
of 80 to 89mmHg as stage 1 hypertensive patients.
Accordingly, the use of antihypertensive agents for pri-
mary intervention is recommended in patients with a
SBP of 130 to 139 mmHg or DBP of 80 to 89 mmHg in
association with increased overall atherosclerotic CVD
risk, and in all patients with a SBP > 140 mmHg or
DBP > 90mmHg [37]. Tighter blood pressure control as
recommended in the 2017 American Hypertension
Guideline has been questioned in (1) young patients that
are at overall low CVD risk as such persons may not
benefit from the respective intervention, and (2) patients
with overall high CVD risk due to the presence of
diabetes, chronic kidney disease, heart failure, coronary
artery disease or/and advancing age. In the latter group,
intensified blood pressure control may increase adverse
events and CVD through the presence of impaired arter-
ial compliance that predisposes to excessive DBP lower-
ing. i.e. below 60mmHg [95]. Nevertheless, considering
the recent 2017 American Hypertension Guideline to-
gether with the facts that the hypertension mediated
CVD risk burden is distinctly large and adequate hyper-
tension control is currently not reached in as much as
93% of Sub-Saharan African hypertensive patients, we
Fig. 2 Statin therapy in Sub-Saharan African patients with RA: suggested indications, doses and targets (points to consider 2.2.1 to 2.2.6). CVD:
cardiovascular disease; MD; moderate dose; HD: high dose; US: ultrasound; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration estimated
glomerular filtration rate; CFUS: carotid and femoral artery ultrasound; GFR: glomerular filtration rate; ACVD: atherosclerotic cardiovascular disease; DM:
diabetes mellitus; TOD: target organ damage; CKD: chronic kidney disease; C: cholesterol; LDL-C: low density lipoprotein cholesterol
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opted to suggest blood pressure management in RA
patients as advocated in the respective recent American
guidelines [37] (PCT2.3.1). In the present context, we
recommend to identify elevated overall CVD risk among
African patients with RA as outlined in PCT2.2.1 to
2.2.6 and Fig. 2.
In keeping with recently reported evidence on the treat-
ment of hypertension in the general population [37–39],
for primary intervention, we suggest angiotensin converting
enzyme inhibitors, angiotensin receptor blockers, calcium
channel blockers and diuretics as preferred first line agents,
and spironolactone, hydralazine and minoxidil as preferred
second line agents in African patients with RA. The use of
a calcium channel blocker or diuretic in combination with
an angiotensin converting enzyme inhibitor or angiotensin
receptor blocker is indicated as initial therapy in most
hypertensive patients except in those with low-risk grade 1
hypertension and in very old (age more than 80 years) and
frail patients [38]. This should also apply particularly in pa-
tients with an autoimmune disease that is associated with
increased CVD like RA. It is noteworthy that beta blockers
are not included among preferred antihypertensive agents.
In this regard, beta blockers can increase arterial wave
reflection [96], which is associated with subclinical athero-
sclerosis in African patients with RA [97]. Also, angiotensin
converting enzyme inhibitor or angiotensin receptor
blocker use was reported to associate independently with
improved glucose metabolism in Africans with RA [72].
In black patients, diuretics and calcium channel
blockers are more effective than angiotensin converting
enzyme inhibitors, angiotensin receptor blockers and
beta blockers in preventing cardiovascular events [37].
Accordingly, the recent American hypertension guide-
lines recommend the inclusion of calcium channel
blockers or diuretics in initial combination regimens in
black hypertensive patients [37]. However, Ojji and col-
leagues recently reported that amlodipine with hydro-
chlorothiazide or perindopril was more effective than
perindopril with hydrochlorothiazide at lowering blood
pressure at 6 months in black Africans [44]. We there-
fore suggest to include a calcium channel blocker in ini-
tial antihypertensive combination regimens among black
African patients with RA.
Lastly, we suggest yearly, monthly and three to six
monthly blood pressure measurement in normotensive
(SBP < 120 mmHg and DBP < 80 mmHg) African RA pa-
tients, and those with uncontrolled and controlled
hypertension, respectively.
Low dose aspirin
As previously noted by Barber and colleagues [98], rec-
ommendations on the use of low dose aspirin in an at-
tempt to reduce CVD risk among patients with RA are
currently lacking. In the general population, low dose
aspirin is recommended in patients with established
CVD [33, 34]. The use of low dose aspirin for primary
intervention of cardiovascular events, particularly in pa-
tients with high CVD risk or diabetes, has been recom-
mended in some guidelines [45]. However, the 2016
European Guideline on CVD prevention in clinical prac-
tice [33] argues against low dose aspirin therapy for pri-
mary prevention of cardiovascular events due to the
increased risk of major bleeding. In 5 randomized con-
trolled trials that were performed subsequent to the year
2000 and formed part of a recent meta-analysis, aspirin
did not reduce all-cause mortality but increased the inci-
dence of major bleeding and intracranial haemorrhage
[45]. These results were also reproduced in participants
with diabetes and patients with a CVD risk > 7% [45]. A
case-crossover and propensity score-matched cohort
study found no protective effect of aspirin on incident
myocardial infarction in RA [99]. A secondary analysis
of the Prospective Randomized Evaluation of Celecoxib
Vs Ibuprofen Or Naproxen (PRECISION) trial also re-
vealed no effect of aspirin on cardiovascular event rates
when used in combination with NSAID and esomepra-
zole, in RA [100]. Given these reported data in the gen-
eral population and RA, we suggest using low dose
aspirin in RA patients with but not without established
atherosclerotic CVD (PTC2.4.1).
Lifestyle factors
Ample evidence was reported in support of the beneficial ef-
fects of body weight control, physical activity and smoking
cessation in the general population [33]. Increased physical
activity also improves CVRF profiles and microvascular and
macrovascular function in RA [101]. In Africans with RA,
dietary intervention prevented the increase in total and LDL
cholesterol concentrations upon suppression of the acute
phase response with conventional targeted DMARD [87].
Among African black persons, those with RA exercise less
frequently but simultaneously experience less prevalent
overall and abdominal obesity compared to their non-RA
counterparts [51]. Nevertheless, the adiposity burden is
markedly larger in black compared to other Africans with
RA [94].
In a recent longitudinal multicentre study on 5638 RA pa-
tients that included African participants, smoking had the
largest population attributable risk associated with incident
cardiovascular events [7]. Black Africans with RA smoke in-
frequently [94]. However, the Gauteng Rheumatoid Evalu-
ation and Assessment Trial (GREAT) revealed that 48% of
female black participants used smokeless tobacco products
in the form of inhaled snuff [102]. Blood levels of the nico-
tine metabolite cotinine, were as large among inhaled snuff
product users as in cigarette smokers [103]. Inhaled snuff
products contain heavy metals and pro-inflammatory micro-
bial substances, particularly bacterial endotoxins that are
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implicated in atherogenesis [103, 104]. The use of inhaled
snuff products is widespread in Sub-Saharan Africa [105].
The urbanization induced rapid epidemiological health
transition in Sub-Saharan Africa is characterized by life-
style changes that result in adverse CVD risk profiles
[106]. Importantly, this process is substantially aggra-
vated by factors that are specific to Sub-Saharan Africa
and include socioeconomic and poverty related stressors,
a lack of resources and primary focus on communicable
diseases, low education levels, inadequate healthcare in-
frastructure and cultural beliefs [106].
Finally, recent meta-analyses documented that both
depression and anxiety are independently associated
with incident CVD event rates [107, 108]. Anxiety may
increase CVD risk through reduced adherence to healthy
behaviours as well as physiological mechanisms includ-
ing autonomic dysfunction, inflammation, endothelial
dysfunction and increased platelet aggregation [109].
The prevalence of depression and anxiety is increased in
RA patients from high income countries [110, 111].
These comorbidities predict long term physical health
outcomes and treatment response in RA [112]. In Sub-
Saharan Africa, public healthcare attendance represents
a low-income marker [113] that is associated with mark-
edly increased tension and depressive symptom burden
in patients with RA [55]. Tension scores are associated
with both carotid intima-media thickness and plaque
presence in black but not white Sub-Saharan Africans
with RA [56].
In line with reported evidence on the role of lifestyle
management aimed at reducing CVD risk in the general
population and RA, we suggest to address the import-
ance of healthy eating habits, adequate physical activity,
smoking and smokeless tobacco cessation and stress and
depressive symptom control with consideration of Sub-
Saharan Africa specific aggravating factors and in order
to reduce CVD risk at presentation and thereafter at
least yearly in patients with RA (PTC2.5.1).
Discussion
This study provides points to consider in the evaluation
and management of CVD risk among black and white
Sub-Saharan African patients with RA. In contrast to the
EULAR recommendations for CVD risk management
[17], we focused on RA and did not address cardiovascu-
lar risk in patients with ankylosing spondylitis and psori-
atic arthritis. This is because the latter two diseases are
distinctly uncommon in Sub-Saharan Africa [114–116]
and, to our knowledge, data on CVD risk inSub-Saharan
African patients with ankylosing spondylitis and psori-
atic arthritis has not been reported to date.
Our evidence base included studies on CVD risk in
RA patients and the general population living in Sub-
Saharan Africa as well as in high income countries, the
latter mostly as recently reported. Further, we perceived
a need for comprehensiveness given the limited re-
sources in the present context. Our approach resulted in
the formulation of 18 points to consider, the contents of
which each differ partially or completely from those of
previously reported recommendations for CVD risk
management in RA patients from high income popula-
tions [1, 2, 17]. The level of agreement with these points
to consider among contributors was consistently high.
The most striking finding is that conventional cardiovas-
cular risk factor based algorithms, which are recom-
mended for use in CVD risk stratification in RA and non-
RA persons from high income populations [1, 2, 17], are
not reliable in identifying Sub-Saharan African black RA
patients with very high risk atherosclerosis [56, 76]. By
contrast, the estimated glomerular filtration rate is useful
to a clinically relevant extent in this context [83]. Our re-
sults support the notion that optimal cardiovascular risk
management is likely to differ substantially in RA patients
from low or middle income compared high income popu-
lations [19].
A most pivotal factor in reducing cardiovascular disease
in RA patients is disease activity control [12, 17]. Current
South African guidelines on the management of RA rec-
ommend the use of biologic agents when conventional
synthetic DMARD therapy fails to adequately control dis-
ease activity [42], which is in line with the respective
EULAR recommendations [40]. Financial support from
medical insurances can often facilitate biological agent use
in South African private healthcare patients. However, re-
ported data indicate that despite the South African guide-
lines, only ~ 0.9% of RA patients that are treated in the
South African public healthcare sector receive biologic
DMARD [117]. This illustrates the ongoing unequal ac-
cess to medical care based on socioeconomic status as one
of the major problems faced by Sub-Saharan Africans. In
this context also, whereas access to vascular ultrasound
and the use of cardiovascular drugs, as proposed in the
present set of points to consider, are currently available at
no extra costs to the patient in the South African public
healthcare sector, the same does not apply to many Afri-
cans living in other Sub-Saharan African countries. As in-
dicated previously in this manuscript, under such
circumstances, recently reported evidence supports the
use a CKD-EPI eGFR of < 80ml/min/1.73m2 and Fra-
mingham score of > 7.5% as indications for lipid lowering
agent therapy when available in black and white Sub-
Saharan Africans, respectively. The provision of cardiovas-
cular drugs in patients that need it will require the involve-
ment of governments’ ministries of health departments.
The evidence base retrieved on CVD risk in Sub-
Saharan African patients with RA comprised mostly of
well-designed cohort studies. However, this investigation
also has important limitations and, accordingly, critical
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implications for future studies. Firstly, currently available
studies on CVD risk in Sub-Saharan African RA patients
frequently have a cross-sectional design and subclinical
CVD as outcomes including atherosclerosis and endothelial
dysfunction, rather than cardiovascular events. Secondly,
whereas data on cardiovascular risk in black and white Sub-
Saharan African patients with RA now exist, such informa-
tion on those from mixed ancestry and Asian minority
population groups are currently missing. Thirdly, most of
the currently available evidence on CVD risk in Sub-
Saharan African RA patients originates in two centres
located in Johannesburg, South Africa. Given the extreme
level of inequality in South Africa [27], the CVD risk burden
could be expected to be similar in South African compared
other Sub-Saharan black patients with RA. However,
whether this is indeed the case requires further studies in
which RA patients from Sub-Saharan African countries
other than South Africa are included. Fourthly, there is a
dearth of data arising from interventional studies. Fifthly,
given the consistently high level of agreement reached in the
present study, the subsequent additional application of a
Delphi method for reaching further agreement may have
been helpful. In this regard also, evidence obtained in gen-
eral population studies from high income countries as was
partially relied on in the present investigation, may not be
consistently applicable in low and middle income popula-
tions. Sixthly, due to limited resources, input from non-
South African EP members may have been hampered as it
was obtained through regular online communications rather
than in person meetings. Nevertheless, this approach proved
to be workable and efficient during previous collaborative
projects among members of the present EP that participated
in this study (e.g. [76, 78]). These shortcomings together
with the reportedly high and increasing CVD burden in low
and middle income populations [18] indicate that further in-
vestigations on cardiovascular risk in Sub-Saharan African
RA patients are urgently needed. We are currently initiating
a multicentre multinational longitudinal study to address
these issues. Further work on the potential role of bio-
markers in cardiovascular risk stratification among Sub-
Saharan African RA patients [19] should also be encouraged.
We anticipate that a need for updating the current points to
consider will arise during the coming 5 years.
Conclusion
Taken together, the findings in the present investigation
indicate that optimal cardiovascular risk management
likely differs substantially in RA patients from low or
middle income compared to high income populations.
There is an urgent need for future multicentre longitu-
dinal studies on CVD risk in Sub-Saharan African
patients with RA. In the meantime, we hope that the
present study facilitates consistent CVD risk manage-
ment in Sub-Saharan African patients with RA.
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